Injectable hyaluronic acid (HA) fillers are widely used in minimally invasive aesthetic medicine for facial and body rejuvenation, as well as for gluteal volumization and contouring. The extensive international use of fillers with various substances has revealed a considerable number of complications that must be recognized for both preventive and therapeutic purposes. The aim of this report is to describe a case of a severe inflammatory reaction occurring 21 days after the injection of 60 cc of HA per gluteal side in a patient who had undergone quadrantectomy for unilateral breast cancer eight months prior, with a negative total-body bone scan, no chemotherapy, and overall good physical and psychological condition. The patient was on tamoxifen therapy in preparation for adnexectomy/total hysterectomy; in agreement with her oncologist and at her request, tamoxifen had been suspended 15 days before the filler injections. The case demonstrated a rapid anti-inflammatory effect achieved exclusively through Quantum Molecular Resonance (QMR®) therapy. The treatment employed Quantum Molecular Resonance (QMR®) technology, widely used in regenerative medicine and physiotherapy for its anti-inflammatory and regenerative effects, mediated through the activation of adult stem cells. The non-invasive protocol consisted of six 20-minute sessions per side, with a 2-day interval between consecutive sessions. QMR® treatment resulted in rapid symptom improvement, with reductions in pain, erythema, and a sensation of tension, without the need for additional corticosteroid therapy. Guidelines for complications related to gluteal hyaluronic acid fillers typically include antibiotic therapy, corticosteroids, possible aspiration, or hyaluronidase. In more severe cases, surgical intervention may be required. In the present case, the patient explicitly requested to avoid corticosteroids. QMR® treatment produced an effective anti-inflammatory response, preventing fibrotic progression and allowing the preservation of the implant. The technology demonstrated both efficacy and scientific plausibility; however, further studies are needed regarding its indications. Nevertheless, this case suggests that QMR® may represent a valid alternative or a useful adjunct to conventional therapeutic strategies for filler-related complications.
This article recommends a lean approach when validating next generation mobile technology (5G) use case solutions in research and innovations projects (R&I). This validation should include a simultaneous and iterative assessment of business value and social acceptance beyond the traditional assessment of technological performance. The context studied in the article is R&I projects funded by the European Commission. Here a consortium of academic and enterprise partners jointly develops 5G product and service solutions for different industry verticals. From the literature review we learn that partnerships and ecosystems accelerate innovations as well as the significance of performing the validation already in the initial steps of the innovation projects. Based on a case study of seven completed 5G R&I projects we revealed that lean methodology for development of use case solutions were not applied. Furthermore, the assessment of potential business values from the 5G use case solutions, was postponed to the later stages of the R&I projects, and that assessing the social acceptance of these solutions were absent. After piloting the lean start-up methodology in an ongoing 5G R&I project (5G SOLUTIONS) we found that the partners advocated technological performance, business value and social acceptance to be ranked equally important to successfully validate the 5G use case solutions in the early steps in the innovation process. The two pilots we executed was performed as online workshops with partners from the 5G SOLUTIONS consortium and the media and entertainment vertical. The prototype was presented and feedback from the stakeholders were collected using surveys and interactive software tools. We recommend further studies and pilots of our lean start-up validation methodology in forthcoming 5G R&I projects funded by Horizon Europe for confirmation of our findings and further refinement.
